Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.

Autor: Paszkiewicz-Kozik E; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Michalski W; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Taszner M; Medical University of Gdansk, Gdansk, Poland., Mordak-Domagała M; Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry, Wroclaw, Poland., Romejko-Jarosińska J; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Knopińska-Posłuszny W; Maritime Hospital, Gdynia, Poland.; Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration's Hospital, Olsztyn, Poland., Najda J; Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Borawska A; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Chełstowska M; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Świerkowska M; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Dąbrowska-Iwanicka A; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Malenda A; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Druzd-Sitek A; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Konecki R; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Kumiega B; Sniadecki Memorial Specialist Hospital, Nowy Sacz, Poland., Osowiecki M; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Ostrowska B; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Szpila T; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Szymański M; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Targoński Ł; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Domańska-Czyż K; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Popławska L; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Giebel S; Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Lange A; Lower Silesian Center for Cellular Transplantation with National Bone Marrow Donor Registry, Wroclaw, Poland., Pluta A; Department of Hematology, Brzozow Oncology Center, Brzozow, Poland., Zaucha JM; Medical University of Gdansk, Gdansk, Poland.; Maritime Hospital, Gdynia, Poland., Rymkiewicz G; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., Walewski J; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2022 Jul; Vol. 198 (1), pp. 73-81. Date of Electronic Publication: 2022 Apr 01.
DOI: 10.1111/bjh.18166
Abstrakt: The efficacy of salvage treatment of diffuse large B-cell lymphoma (DLBCL) patients who relapse or progress (rrDLBCL) after initial therapy is limited. Efficacy and safety of ofatumumab with iphosphamide, etoposide and cytarabine (O-IVAC) was evaluated in a single-arm study. Dosing was modified for elderly patients. Patients received up to six cycles of treatment. The primary end-point was the overall response rate (ORR). Patients were evaluated every two cycles and then six and 12 months after treatment. Other end-points included progression-free survival (PFS), event-free survival (EFS), overall survival (OS) and safety. Seventy-seven patients received salvage treatment with O-IVAC. The average age was 56.8 years; 39% had an Eastern Cooperative Oncology Group (ECOG) performance status of at least 3; 78% had disease of Ann Arbor stage 3 or 4; 58% received one or more prior salvage therapies. The ORR for O-IVAC was 54.5%. The median duration of study follow-up was 70 months. The median PFS and EFS were 16.3 months each. The median OS was 22.7 months. Age, ECOG performance status and the number of prior therapy lines were independent predictors of survival. Treatment-related mortality was 15.5%. O-IVAC showed a high response rate in a difficult-to-treat population and is an attractive treatment to bridge to potentially curative therapies.
(© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: